Pui, CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, and Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N. Engl. J. Med. 336: 1781-1787, 1997.
Synold TW, Tetef ML, Doroshow JH. Antineoplastic activity of continuous exposures to dexrazoxane: potential new role as a topoisomerase-II inhibitor. Semin. Oncol. 25: 93-99, 1998.
Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, Doroshow JH.
Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematologic toxicity. Clin. Cancer Res. 4: 2349-2355, 1998.
McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S,Spicer D, Bissett, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 6(7):2677-84, 2000.
Raschko, JW, Synold TW, Chow W, Coluzzi P, Hamasaki V, Leong L, Margolin K, Morgan RJ Jr., Shibata SI, Somlo G, Tetef ML, Yen Y, and Doroshow JH. A Phase I Study of Carboplatin and Etoposide Administered in Conjunction with Dipyridamole, Prochlorperazine and Cyclosporine A. Cancer Chemother Pharmacol. 46(5):403-10, 2000.
Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood. 97(9):2839-2845, 2001.
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.Nat. Med. 7(5): 584-590, 2001.
Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, and Doroshow JH. Phase I trial of ninety-six hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res. Jun;7(6):1569-76, 2001.
Margolin K, Synold T, Longmate J, Doroshow JH. Methodologic guidelines for the design of high-dose chemotherapy regimen. Biol Blood Marrow Transplant. 7:414-432, 2001.
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates
drug metabolism and efflux. Nat Med. 7:584-590, 2001.
Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97: 2839-2845, 2001.
Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen M, Newman R, Baratta T, Doroshow JH. Dolastatin-10 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Invest. New Drugs 19: 335-340, 2002.
Doroshow JH, Synold T, Gandara D, Mani S, Remick S, Mulkerin D, Hamilton A, Sharma S, Ramanathan R, Lenz HJ, Graham M, Longmate J, Takamoto C, and Ivy P. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A Preliminary report of the national Cancer Institute Organ Dysfunction Working Group. Semin Oncol 30(4 Suppl 15):14-9, 2003.
ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs. 2003 Aug;21(3):291-8, 2003.
Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9:5896-901, 2003.
Doroshow JH, Synold T. Pharmacological basis for high-dose chemotherapy. In: Hematopoietic Cell Transplantation, E.D. Thomas, K.G. Blume, and S.J. Forman, eds. 3rd edition, Blackwell Science, Inc., Malden, MA, pp 130-157, 2004.
Besaratinia A, Synold TW, Chen H-H, Chang C, Xi B, Riggs AD, Pfeifer GP. DNA lesions induced by ultraviolet A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. PNAS 102(29):10058-63, 2005.
Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G. The Effect of Height on Paclitaxel Nerve Damage. J Neuro-Oncol. 74(2):207-10, 2005.
Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in Metastatic Melanoma: a Phase II Trial of the California Cancer Consortium. Cancer. 104(5):1045-8, 2005.
Figarola J, Scott S, Loera S, Xi B, Synold TW, Weiss, L, Rahbar S. Prevention of Early Renal Disease, Dyslipidaemia, and Lipid Peroxidation in STZ-Diabetic Rats by LR-9 and LR-74, Novel AGE Inhibitors. Diabetes Metab Res Rev. [Epub ahead of print], 2005.
Lara, P., Mack, P., Synold, T., Longmate, J., Frankel, P., Gumerlock, P., Doroshow, J., and Gandara, D. The Cyclin-Dependent Kinase Inhibitor UCN-01 (7-hydroxystaurosporine) plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. Clin. Cancer Res. 11(12):4444-50, 2005.
Synold TW. Vinca Alkaloids. In Clinical Pharmacology of Cancer. D.R. Newell, J.H.M. Schellens, H.L. McLeod, eds, Oxford University Press., Oxford, UK, 2005.
Synold TW, McLeod HL: Pharmacogenomics. In Remmington: The Science and Practice of Pharmacy, 21st edition, The University of Sciences in Philadelphia, Philadelphia, PA, 2005.
Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. A phase I study of oxaliplatin in combination with gemcitabine: correlation ofclinical outcome with gene expression. Cancer Chemother Pharmacol. 59(4): 549-57, 2007.
Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007 Jan 16; [Epub ahead of print]
Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 May 17; [Epub ahead of print].
Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer. 17(2):373-8, 2007.
Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Res. 13(4):1232-7, 2007.
Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007 Aug 15;13(16):4832-9.
Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P; National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007 Jun 15;13(12):3660-6.
Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 2007 Sep 26; [Epub ahead of print]
Lee CW, Bélanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2007 Oct 26; [Epub ahead of print]
Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Synold TW, Vasist LS, Winquist E. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.Invest New Drugs. 2007 Nov 24; [Epub ahead of print]
Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). nvest New Drugs. 2008 Jan 15; [Epub ahead of print]
Twardowski P, Smith-Powell L, Carroll M VanBalgooy C, Ruel C, Frankel P, Synold T. Biologic markers of angiogenesis: Circulating endothelial cells in patients with advanced malignancies treated on a Phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest. 2008 Feb;26(1):53-9.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 02/08.
